ARTICLE | Management Tracks
Charl van Zyl to succeed Dunsire at Lundbeck
Plus: Raj Kannan named CEO at I-Mab, and updates from uniQure, Immodulon, Ichnos and more
June 26, 2023 11:34 PM UTC
Charl van Zyl will succeed Deborah Dunsire as President and CEO of H. Lundbeck A/S (CSE:HLUN) no later than Oct. 1. van Zyl is EVP, and head of neurology for Europe and international markets at UCB S.A. (Euronext:UCB). Dunsire, who is retiring, revamped Lundbeck’s strategy to create a more innovation-focused pipeline.
Immunotherapies company I-Mab Biopharma (NASDAQ:IMAB) named Raj Kannan as CEO and board member. Kannan was CEO of Aerie Pharmaceuticals Inc. and Chiasma Inc...